Introduction: Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity,
urine volume and factors that are known to affect urine volume and between actual urine volume and these factors.
Results: Canagliflozin transiently increased urine volume and urinary sodium excretion on Day 1 with a return to baseline levels thereafter.
Canagliflozin administration increased urinary glucose excretion, which was sustained during repeated-dose administration. Plasma atrial natriuretic peptide (ANP) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) levels decreased, while plasma renin activity increased. On Day 1 of treatment, changes in sodium and potassium excretion were closely correlated with changes in urine output. A post hoc multiple regression analysis showed changes in sodium excretion and water intake as factors that affected urine volume change at Day 1. Furthermore, relative to that at baseline, canagliflozin decreased blood glucose throughout the day and increased plasma total GLP-1 after breakfast.
Conclusion:
Canagliflozin induced transient sodium excretion and did not induce water intake at Day 1; hence, natriuresis rather than glucose-induced osmotic diuresis may be a major factor involved in the canagliflozin-induced transient increase in urine output. In addition, canagliflozin decreased plasma ANP and NT-proBNP levels and increased plasma renin activity, which may be a compensatory mechanism for sodium retention, leading to subsequent urine output recovery. Clinical trial registration: UMIN000019462.
INTRODUCTION
Typical features of type 2 diabetes mellitus (T2DM) are insulin resistance of various organs and reduced glucose-stimulated insulin secretion [1] . In addition, the kidney plays a crucial role in regulating glucose levels by mediating the reabsorption of glucose filtered through glomeruli. Renal glucose reabsorption is mediated by sodium glucose co-transporter 2 (SGLT2) and SGLT1, with SGLT2 playing the major role because of its specific localization in the kidney and higher capacity than SGLT1.
SGLT2 expression is increased in T2DM; hence, higher amounts of glucose are reabsorbed by the kidney, thereby contributing to the sustained elevation of serum glucose levels in patients with diabetes [2, 3] . SGLT2 inhibitors reduce blood glucose levels by suppressing this glucose reabsorption in an insulin-independent manner. Furthermore, SGLT2 inhibitors have demonstrated not only a hypoglycemic effect but also a body weight-reducing effect through calorie loss associated with glycosuria and a hypotensive effect [3] [4] [5] . In addition to control of blood glucose, control of body weight and blood pressure play important roles in preventing complications associated with T2DM [6] . Thus, a series of SGLT2 inhibitors have become new therapeutic options for T2DM [3] [4] [5] [7] [8] [9] . Several studies of SGLT2
inhibitors have been conducted to assess the cardiovascular outcomes [10] , and it was reported that the SGLT2 inhibitor empagliflozin reduced heart failure hospitalization as well as cardiovascular and all-cause deaths in T2DM patients with high CVD risk (EMPA-REG OUTCOME trial) [11] .
One possible mechanism underlying the cardiovascular benefit of empagliflozin is related to its osmotic diuretic effect by glycosuria [12, 13] . However, osmotic diuresis-induced increase in urine volume, loss of body fluid, and risk of dehydration have been of concern with SGLT2 inhibitor treatment [14, 15] . Canagliflozin is an SGLT2 inhibitor approved in North America, Europe, Latin America, and Asia-Pacific regions for treatment of T2DM [16] [17] [18] . We previously conducted a pharmacokinetic and pharmacodynamic study of canagliflozin in Japanese patients with T2DM, in which administration of canagliflozin at 25, 100, 200, or 400 mg once-daily increased 24-h urine volume by 400-700 mL on Day 1, with a return to baseline from Day 2 onward. There was also an increase in urinary sodium (Na) excretion on Day 1 with a return to baseline thereafter, while water intake increased in the 400-mg group on Day 1, but did not change in the other dosage groups [19] (ESM Table 1 ). Although some previous studies reported that SGLT2 inhibitor-induced increases in urine volume were short-lived [20] [21] [22] , the detailed nature of the transient effect remains unknown. For the proper clinical use of the SGLT2 inhibitor canagliflozin, it is important to confirm this transient increase in urine volume and elucidate the underlying mechanism. Therefore, the purpose of this study was to investigate the mechanism underlying canagliflozin-induced diuresis in Japanese T2DM patients by measuring factors that affect homeostasis of body fluid and mineral balance.
METHODS

Subjects and Study Design
This single-arm, exploratory study was carried out to investigate the factors involved in the 
Endpoints and Assessments
The primary endpoints were correlations between changes from baseline in urine volume and factors known to affect urine volume, and between actual urine volume and these factors. The factors examined included water intake, urinary glucose excretion, urinary electrolyte excretion (Na To evaluate the reproducibility of the present study, correlation and multiple regression analyses of a previous study [19] were performed by Takumi Information Technology (Tokyo, Japan) using SAS 9.4 (SAS Institute Inc.).
RESULTS
Patient Disposition and Baseline Characteristics
The baseline demographic and disease characteristics of the patients are summarized in Table 1 . A total of 14 patients were enrolled, of whom 13 received the treatment and 12 (10 males and 2 females) completed the study. One female patient withdrew from the study because of AEs including anorexia, malaise, nausea, and vomiting.
Effect on Urine Volume and Changes from Baseline
Canagliflozin treatment showed a trend towards increased urine volume by 267.1 mL (95% CI:
-70.5-604.7 mL) on Day 1. Subsequently, the urine volume returned to baseline from Day 2 to Day 4, and showed another increase trend on Day 5. As the dropout patient had abnormal water intake and urine volume after hospitalization, we also performed the analysis without this patient as a reference, and found that canagliflozin treatment increased urine volume by 362.9 mL (95% CI: 71.6-654.2 mL) on Day 1 ( Table 2 ).
Effect on Parameters that Reflect Urine Volume
Canagliflozin administration increased urinary glucose excretion on Day 1, and this level was maintained thereafter (Fig. 1a) . Water intake did not change appreciably until Day 4, and showed a trend towards an increase on Day 5 (Fig. 1b) . Urinary Na excretion tended to (Fig. 1c) . Urinary K excretion tended to decrease on Day 2 and thereafter (Fig. 1d) .
Urine osmolality showed an increase immediately after canagliflozin administration (Fig. 1e) . Serum osmolality, blood urea nitrogen-to-serum creatinine ratio (BUN/CRE), and hematocrit (Ht) did not change during treatment ( Fig. 1f-h ).
Effect on Plasma Hormone Levels/Enzyme Activity
The plasma concentrations of hormones and enzyme activity related to body fluid control were measured at predetermined time points, and their AUCs over 24 h were calculated. Canagliflozin caused a reduction in
NT-proBNP at 24 h after administration, a decrease in ANP from 4 h, and an increase in renin activity at Day 5. Reduced AUCs of NT-proBNP and ANP were observed on Day 5 and Days 1 and 5, respectively, and that of renin activity increased on Day 5 ( Fig. 2a-c ; Table 3 ). The plasma concentrations of aldosterone and vasopressin were not appreciably affected by the treatment ( Fig. 2d, e ; Table 3 ).
Correlation and Multiple Regression Analyses
Spearman's correlation coefficients were calculated between changes from baseline in urine volume and each factor, and also between urine volume and each factor (Table 4) Table 4 ). A similar analysis was performed using data from a previous study [19] , which found that change from baseline in urine volume was correlated with changes from baseline in urinary Na and K excretions on Day 1 and was not correlated with Table 2 (Table 5 ). Similar analyses were performed using previous study data [19] , and the changes in urinary Na excretion (p = 0.0031) and water consumption (p\0.0001) were selected as determinants of urine volume increase (R 2 = 0.4153; Table 5 ). The regression coefficients of the variables were similar in this and the previous studies: 8.837 and 7.496 for urinary Na excretion and 0.420 and 0.361 for water intake, respectively.
Effect on Blood Glucose and Total GLP-1 Figure 3 shows the 24-h blood glucose profile, AUC over 2 h for postprandial glucose after each (Fig. 3a, b) . The increases in total blood GLP-1 after breakfast on Days 1 and 5 were higher than those before treatment (Day 0; Fig. 3c, d ; ESM Table 3 ).
Effect on Laboratory Tests
Plasma insulin was reduced by canagliflozin treatment. Plasma ketone bodies increased on Day 1 and remained elevated. Body weight and blood pressure were not appreciably changed by the treatment (ESM Table 4 ).
AEs
One female patient withdrew from the study because of anorexia, malaise, nausea, and vomiting. The investigator concluded that the possibility that these AEs were causally related to the study drug could not be excluded, but 
DISCUSSION
The present study demonstrated that canagliflozin produced a mild increase in urine 
The pharmacological effect of canagliflozin on urinary glucose excretion or renal threshold for glucose excretion is nearly saturated at doses above 100 mg [19] . Therefore, we performed a similar analysis using all data with different doses over 100 mg combined in that study to confirm the reproducibility of the present study but no appreciable changes in plasma vasopressin and aldosterone, were observed.
We performed correlation and multiple regression analyses using the data of present and previous studies [19] . Regarding changes from baseline, Na, and K were correlated with urine volume. Meanwhile, the actual value of urine volume was correlated with water intake on Days 0, 1, and 5. Multiple regression analysis showed changes in Na excretion and water intake as factors that affected urine volume change on Day 1. Interestingly, two same factors were selected and the regression coefficients were closed in both studies, which suggested the reproducibility of the present study. Water intake was highly correlated with actual urine volume before and during treatment, and was not affected by the treatment; the correlation is thought to reflect the general body response. Meanwhile, canagliflozin induced transient Na excretion on Day 1, and the change in Na excretion was closely correlated with change in urine volume.
Thus, the transient increase in Na excretion is thought to have played a major role in the canagliflozin-induced increase in urine volume.
In the present study, change in urinary glucose excretion was correlated with change in urine volume on Day 1. It should be noted that urinary glucose excretion was fairly constant from Day 1 to Day 5, despite urine volume, as well as urinary Na excretion, canagliflozin-induced diuresis is likely to reflect natriuresis, not glucose-driven osmotic diuresis. This is consistent with the results of a recent simulation study using a mathematical model of the rat nephron, which demonstrated that SGLT2 inhibition-induced increase in urine volume is expected to reflect natriuresis rather than osmotic diuresis [23] . Increases in urine output and urinary Na excretion were also reported in Japanese patients with T2DM and heart failure after treatment with ipragliflozin for 4 days [24] , although the patient profile was different from that in the present study.
In the present and previous studies, the actual value of urine osmolality was negatively correlated with the actual value of urine volume before and during treatment. In general, increasing urine volume dilutes the solutes, resulting in decreased urine osmolality. The negative correlation between increased urine volume and urine osmolality is also likely to be attributed to the physiological response.
The present study also demonstrated that canagliflozin decreased plasma ANP and NT-proBNP levels and increased plasma renin activity. Change in plasma aldosterone was negatively correlated with change in urine volume on Day 5. As these factors are involved in regulating Na excretion, working in concert or counteracting each other in the distal portion of the nephron, these changes may contribute to increased renal tubular reabsorption of Na in a compensatory manner.
A similar compensatory mechanism was reported for the action of diuretics such as furosemide and hydrochlorothiazide, with the natriuretic action abolished by continued treatment [25] , which is considered to be mediated through a decrease in plasma ANP and activation of the renin-angiotensin system. The 4-day ipragliflozin treatment significantly decreased plasma ANP and BNP and increased plasma renin activity, while plasma aldosterone tended to increase, but without statistical significance [24] . A 12-week treatment with dapagliflozin was reported to be associated with increases in plasma renin activity and aldosterone [26] . The study also The limitations of the study were the small sample size, short-term nature, and lack of control group. Urine volume is variable among patients, days, and ambient conditions. However, the samples in the present study were obtained from hospitalized patients to ensure the controlled and reliable baseline data (before administration). In addition, we performed similar analyses using our previous study data to evaluate the reproducibility of the present study. Therefore, we think this paper has clinical value. The long-term effect and mechanism of canagliflozin for urine volume remains to be addressed.
CONCLUSIONS
Natriuresis is suggested to be the primary factor involved in the canagliflozin-induced transient increase in urine output on Day 1. Decreased plasma ANP and NT-proBNP and increased plasma renin activity may be a compensatory mechanism for subsequent urine output recovery. 
